← Back to all trials
Recruiting
NCT07610278
A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia
Conditions: Hypercholesterolaemia
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 120
Sponsor: Novartis Pharmaceuticals
Location: G and L Research LLC Foley Alabama
Summary
This is a multicenter, randomized, double-blind, factorial design Phase 2 study to evaluate the pharmacodynamics, safety and tolerability of a combination of QCZ484 and inclisiran compared to QCZ484, inclisiran, and placebo in participants with hypertension and concomitant hypercholesterolemia.
Eligibility Criteria
Inclusion Criteria:
* Males or females aged 18 to 75 years.
* Diagnosis of primary hypertension.
* Treatment with either no, or up to 2 antihypertensive medications at a stable dose for at least 4 weeks preceding screening.
* Systolic blood pressure ≥140 and \
Source: ClinicalTrials.gov (NCT07610278). StuddyBuddy aggregates publicly available trial information.
